Doctoral School, University of Medicine and Pharmacy of Craiova, Romania;
Rom J Morphol Embryol. 2021 Jul-Sep;62(3):807-817. doi: 10.47162/RJME.62.3.19.
Depression represents a public health issue because it significantly increases the risk of disabilities and premature mortality, decreases the quality of life, and increases the costs of care. The incomplete remissions favor the aggravation of neurobiological dysfunctions and pathogenesis of severe somatic comorbidities. The etiopathogenic mechanisms of depression are complex and involve multisystemic risk factors (genetic, neuroanatomic, neurobiochemical, neuroendocrine and psychosocial). Cognitive behavioral therapy (CBT) is used in all the stages of depression, as independent therapeutic method or as support of pharmacotherapy.
PATIENTS, MATERIALS AND METHODS: This study has evaluated the therapeutic response of depression in M (medication) group with 136 patients under pharmacotherapy, compared with P (psychotherapy and medication) group with 137 patients treated simultaneously with medication and CBT, and the factors that can improve therapeutic management.
Patients with depression had predominantly a reactive onset, recurrent evolution of at least four episodes, and frequent somatic comorbidities. After treatment, a significant improvement of depressive symptomatology was recorded especially in M group (72.06%), compared to P group (88.32%), p<0.01, as well as a significant difference in regaining functional skills (69.12% - M group, 93.43% - P group; p<0.001). The therapeutic response was significantly correlated with age (p<0.01), social-economical involvement and education level.
CBT demonstrated efficiency in the treatment of major depressive disorder in association with pharmacotherapy. The therapeutic approach should rely on the pathogenic biological models that would highlight the prediction indicators for the therapeutic response and for the evolution of depression, as well as considering the psychological profile of each patient.
抑郁症是一个公共卫生问题,因为它会显著增加残疾和早逝的风险,降低生活质量,并增加护理成本。不完全缓解有利于神经生物学功能障碍的恶化和严重躯体共病的发病机制。抑郁症的病因发病机制复杂,涉及多系统危险因素(遗传、神经解剖、神经生化、神经内分泌和心理社会)。认知行为疗法(CBT)用于抑郁症的所有阶段,无论是作为独立的治疗方法还是作为药物治疗的支持。
患者、材料和方法:本研究评估了药物治疗组(M 组)的 136 例抑郁症患者和药物治疗联合认知行为治疗组(P 组)的 137 例患者的治疗反应,以及可以改善治疗管理的因素。
抑郁症患者主要表现为反应性发作,至少有四次复发,且常伴有躯体共病。治疗后,M 组(72.06%)的抑郁症状显著改善,明显优于 P 组(88.32%),p<0.01,功能恢复方面也存在显著差异(M 组 69.12%,P 组 93.43%;p<0.001)。治疗反应与年龄(p<0.01)、社会经济状况和教育水平显著相关。
CBT 与药物治疗联合治疗重度抑郁症有效。治疗方法应依赖于致病的生物学模型,这些模型将突出治疗反应和抑郁症演变的预测指标,并考虑到每位患者的心理特征。